

Stanford Cancer Institute

Cancer Cell Therapy

Classical Hodkins Lymphoma (cHL)

>12-75 Years

Relapsed or Refractory CD30 Positive Classical Hodgin Lymphoma

CCT5040

Phase II
CD30.CAR-T in
Adult & Pediatric
Relapsed/Refractory CD30
Positive Classical
Hodgin Lymphoma

PI: Arai
Sponsor: Pending

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Enrollment on Hold

Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu